Abstract
1. Stop injection/infusion immediately
2. Get extravasation kit
3. Put on (sterile) gloves
4. Replace infusion lead or syringe with 5 ml disposable syringe and aspirate slowly as much as possible of the extravasated drug; Cave! do not exert pressure on extravasation area
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Original articles
Oettgen HF, Stephenson PA, Schwartz MK, et al: Toxicity of E. coli L- asparaginase in man. Cancer 25: 253–278, 1970.
Haskell CM, Canellos GP, Leventhal BG, et al: L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med 281: 1028–1034, 1969.
Barr RD, Benton SG, Belbeck LW: Soft-tissue necrosis induced by extravasated cancer chemotherapeutic agents. J Natl Cancer Inst 66: 1129–1136, 1981.
Secondary literature
Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.
Stanley A: Managing complications of chemotherapy administration. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 4th edition: 119–193, 2002.
Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S. Schneider Verlag, 6th edition: 1–17, 1999.
Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.
Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.
Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer -Chemotherapy Handbook. Appleton & Lange, 2nd edition: 109–118, 1994.
Cox K, Stuart-Harris R, Abdini G, et al: The management of cytotoxic-drug extravasation: guide-lines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust 148: 185–189, 1988.
Fuxius S, Unger C: Pegaspargase. Arzneimitteltherapie 16: 170–173, 1998.
Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: -Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, vol 1, 2nd edition A42–44, 1997.
Dorr RT, Von Hoff DD: Drug monographs: asparaginase. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 201–209, 1994.
Summary of product characteristics Asparaginase medac (-Germany), medac, March 2004.
Krämer I, Stützle M: Zytostatika-Paravasation – Wie ist vorzugehen? Krankenhauspharmazie 23: 261–268, 2002.
Albanell J, Baselga J: Systemic therapy emergencies. Semin Oncol 27: 347–361, 2000.
Koppel RA, Boh EE: Cutaneous reactions to chemotherapeutic agents. Am J Med Sci 321: 327–335, 2001.
Alley E, Green R, Schuchter L: Cutaneous toxicities of cancer therapy. Curr Opin Oncol 14: 212–216, 2002.
Jordan K, Grothe W, Schmoll HJ: Paravasation von Zytostatika: Prävention und Therapie. Dtsch Med Wochenschr 130: 33–37, 2005.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag/Wien
About this chapter
Cite this chapter
Mader, I., Fürst-Weger, P., Mader, R., Nogler-Semenitz, E., Wassertheurer, S. (2010). L-Asparaginase. In: Extravasation of Cytotoxic Agents. Springer, Vienna. https://doi.org/10.1007/978-3-211-88893-3_13
Download citation
DOI: https://doi.org/10.1007/978-3-211-88893-3_13
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-88889-6
Online ISBN: 978-3-211-88893-3
eBook Packages: MedicineMedicine (R0)